Specifically, the antifibrotic functions of small-molecule compounds were achieved by improving the renin-angiotensin system, oxidative stress and inflammation, TGF-β/Smad and Wnt/β-catenin signaling pathway dysregulation, uremic toxin, amino acid, and lipid metabolism disorders [24]. Here, TGFB1 is linked to Disorder of lipid metabolism.